| Date Filed | Type | Description |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/14/2023 |
8-K
| Investor presentation, Quarterly results |
| 08/03/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/25/2023 |
8-K
| Investor presentation |
| 05/09/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/09/2023 |
8-K
| Quarterly results |
| 04/25/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/25/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/25/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/03/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/02/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/02/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/02/2023 |
8-K
| Quarterly results |
| 02/09/2023 |
SC 13G/A
| FMR LLC reports a 6.9% stake in XILIO THERAPEUTICS INC |
| 01/25/2023 |
SC 13G
| Octagon Capital Advisors LP reports a 8.8% stake in XILIO THERAPEUTICS, INC. |
| 01/09/2023 |
8-K
| Investor presentation |
| 12/29/2022 |
SC 13G/A
| Flynn James E reports a 0% stake in Xilio Therapeutics, Inc. |
| 11/21/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 11/14/2022 |
SC 13G/A
| RA CAPITAL MANAGEMENT, L.P. reports a 0% stake in XILIO THERAPEUTICS, INC. |
| 11/09/2022 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 11/09/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/09/2022 |
8-K
| Investor presentation, Quarterly results |
| 09/15/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/09/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/09/2022 |
8-K
| Quarterly results |
| 07/28/2022 |
8-K
| Quarterly results |
| 06/16/2022 |
8-K
| Quarterly results |
| 06/13/2022 |
8-K
| Quarterly results |
| 05/12/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 05/12/2022 |
8-K
| Quarterly results |
| 04/26/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/26/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/01/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/01/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
|